Cargando…

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer

The aim of this study was to evaluate if prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher detection rate compared to standard contrast CT imaging for patients with a rising prostate-specific antigen (PSA) following definitive treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Asokendaran, Marcus Edward, Meyrick, Danielle P., Skelly, Laura A., Lenzo, Nat P., Henderson, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714155/
https://www.ncbi.nlm.nih.gov/pubmed/31516365
http://dx.doi.org/10.4103/wjnm.WJNM_59_18
_version_ 1783447002230554624
author Asokendaran, Marcus Edward
Meyrick, Danielle P.
Skelly, Laura A.
Lenzo, Nat P.
Henderson, Andrew
author_facet Asokendaran, Marcus Edward
Meyrick, Danielle P.
Skelly, Laura A.
Lenzo, Nat P.
Henderson, Andrew
author_sort Asokendaran, Marcus Edward
collection PubMed
description The aim of this study was to evaluate if prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher detection rate compared to standard contrast CT imaging for patients with a rising prostate-specific antigen (PSA) following definitive treatment (i.e., curative radical prostatectomy, radiotherapy, and brachytherapy) for prostate cancer in a private hospital setting. A retrospective single-site clinical audit was conducted on 150 PSMA PET/CT scans done for patients with a rising PSA after definitive treatment for prostate cancer. All studies were performed using I and T Ga-68 PSMA produced on a Scintomics radiopharmaceutical unit (Munich). All scans were performed on a GE 710 PET/CT scanner. All studies were compared to standard CT and other imaging. Of the 150 patients who had a (68)Gallium (Ga)-PSMA PET/CT for a rise in their PSA levels, 102/150 (68%) of patients had PSMA-avid scans compared to the conventional imaging group which had an overall detection rate of 42% (63/150). The rates of detection were 100%, 90%, 92%, 67%, and 25% at PSA levels of >10 μg/L, 5–10 μg/L, >1.5 μg/L, 0.5–1.5 μg/L, and <0.5 μg/L, respectively. PSMA PET/CT also solely picked up 39/102 (38%) of prostate cancer relapses compared to the conventional imaging group. In our study of 150 patients with biochemical recurrence of prostate cancer, (68)Ga-PSMA PET/CT demonstrated a superior detection rate (P < 0.05) compared to conventional imaging, including patients with low PSA levels (<0.5 μg/L).
format Online
Article
Text
id pubmed-6714155
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-67141552019-09-12 Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer Asokendaran, Marcus Edward Meyrick, Danielle P. Skelly, Laura A. Lenzo, Nat P. Henderson, Andrew World J Nucl Med Original Article The aim of this study was to evaluate if prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher detection rate compared to standard contrast CT imaging for patients with a rising prostate-specific antigen (PSA) following definitive treatment (i.e., curative radical prostatectomy, radiotherapy, and brachytherapy) for prostate cancer in a private hospital setting. A retrospective single-site clinical audit was conducted on 150 PSMA PET/CT scans done for patients with a rising PSA after definitive treatment for prostate cancer. All studies were performed using I and T Ga-68 PSMA produced on a Scintomics radiopharmaceutical unit (Munich). All scans were performed on a GE 710 PET/CT scanner. All studies were compared to standard CT and other imaging. Of the 150 patients who had a (68)Gallium (Ga)-PSMA PET/CT for a rise in their PSA levels, 102/150 (68%) of patients had PSMA-avid scans compared to the conventional imaging group which had an overall detection rate of 42% (63/150). The rates of detection were 100%, 90%, 92%, 67%, and 25% at PSA levels of >10 μg/L, 5–10 μg/L, >1.5 μg/L, 0.5–1.5 μg/L, and <0.5 μg/L, respectively. PSMA PET/CT also solely picked up 39/102 (38%) of prostate cancer relapses compared to the conventional imaging group. In our study of 150 patients with biochemical recurrence of prostate cancer, (68)Ga-PSMA PET/CT demonstrated a superior detection rate (P < 0.05) compared to conventional imaging, including patients with low PSA levels (<0.5 μg/L). Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6714155/ /pubmed/31516365 http://dx.doi.org/10.4103/wjnm.WJNM_59_18 Text en Copyright: © 2019 World Journal of Nuclear Medicine http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Asokendaran, Marcus Edward
Meyrick, Danielle P.
Skelly, Laura A.
Lenzo, Nat P.
Henderson, Andrew
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
title Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
title_full Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
title_fullStr Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
title_full_unstemmed Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
title_short Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
title_sort gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714155/
https://www.ncbi.nlm.nih.gov/pubmed/31516365
http://dx.doi.org/10.4103/wjnm.WJNM_59_18
work_keys_str_mv AT asokendaranmarcusedward gallium68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographycomparedwithdiagnosticcomputedtomographyinrelapsedprostatecancer
AT meyrickdaniellep gallium68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographycomparedwithdiagnosticcomputedtomographyinrelapsedprostatecancer
AT skellylauraa gallium68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographycomparedwithdiagnosticcomputedtomographyinrelapsedprostatecancer
AT lenzonatp gallium68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographycomparedwithdiagnosticcomputedtomographyinrelapsedprostatecancer
AT hendersonandrew gallium68prostatespecificmembraneantigenpositronemissiontomographycomputedtomographycomparedwithdiagnosticcomputedtomographyinrelapsedprostatecancer